Laden…
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
Vilazodone is an antidepressant that works by inhibiting serotonin reuptake and partial agonism at the 5-HT1A receptor. It is used for the treatment of major depression and may have anxiolytic effects. The combination of these mechanisms distinguishes it from classical SSRIs. Side effects are comparable to other serotonergic antidepressants.
Class
Serotonin-Wiederaufnahmehemmer
Pharmacological context
Mechanism
5-HT1A agonist, SERT inhibitor
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Vilazodone acts through the following pharmacological mechanisms:
Designations
IUPAC: 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazino]coumarilamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT1A-Rezeptor ist ein Gi/Go-gekoppelter Serotoninrezeptor, der als Autorezeptor auf serotonergen Neuronen und als Heterorezeptor in verschiedenen Hirnregionen vorkommt. Er moduliert Angst, Stimmung und Kognition.
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Reported range 20 mg
Oral
| Tier | Dosage |
|---|---|
| Light | 10 mg |
| Reported | 20 mg |
| Strong | 40 mg |
Oral
Onset
1–2 weeks
Peak
4–6 weeks
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Übelkeit, Durchfall und Schlaflosigkeit.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.